Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Erica B. Schleifman"'
Autor:
Sarah M. Paul, Filippo de Marinis, Rafal Dziadziuszko, David S. Shames, Shirish M. Gadgeel, Hye Ryun Kim, Todd Riehl, Natasha B. Leighl, Osvaldo Arén Frontera, Ernest Nadal, Mark Yan, Jorge Arturo Alatorre-Alexander, Daniel Shao-Weng Tan, Ji Youn Han, Maurice Pérol, Dae Ho Lee, Rajesh Patel, Simonetta Mocci, Zoe June Assaf, M. Mathisen, Erica B. Schleifman, Tony Mok, Solange Peters, Virote Sriuranpong, Gilberto de Castro Junior
Publikováno v:
Journal of Thoracic Oncology. 16:2040-2050
Introduction The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of
Autor:
Doris Kim, YounJeong Choi, James Ireland, Oded Foreman, Rachel N Tam, Rajesh Patel, Erica B Schleifman, Maipelo Motlhabi, Dorothy French, Cheryl V Wong, Eric Peters, Luciana Molinero, Rajiv Raja, Lukas C Amler, Garret M Hampton, Mark R Lackner, Omar Kabbarah
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0165856 (2016)
In the age of personalized medicine stratifying tumors into molecularly defined subtypes associated with distinctive clinical behaviors and predictable responses to therapies holds tremendous value. Towards this end, we developed a custom microfluidi
Externí odkaz:
https://doaj.org/article/6b49b7df79184ff786c816a2ccf4acec
Autor:
Erica B Schleifman, Rachel Tam, Rajesh Patel, Alison Tsan, Teiko Sumiyoshi, Ling Fu, Rupal Desai, Nancy Schoenbrunner, Thomas W Myers, Keith Bauer, Edward Smith, Rajiv Raja
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90761 (2014)
Molecular profiling of tumor tissue to detect alterations, such as oncogenic mutations, plays a vital role in determining treatment options in oncology. Hence, there is an increasing need for a robust and high-throughput technology to detect oncogeni
Externí odkaz:
https://doaj.org/article/d1158b5fc13d4e72b1efa7d3f70cf372
Autor:
Erica B Schleifman, Rupal Desai, Jill M Spoerke, Yuanyuan Xiao, Cheryl Wong, Ilma Abbas, Carol O'Brien, Rajesh Patel, Teiko Sumiyoshi, Ling Fu, Rachel N Tam, Hartmut Koeppen, Timothy R Wilson, Rajiv Raja, Garret M Hampton, Mark R Lackner
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88401 (2014)
Patients with newly diagnosed, early stage estrogen receptor positive (ER+) breast cancer often show disease free survival in excess of five years following surgery and systemic adjuvant therapy. An important question is whether diagnostic tumor tiss
Externí odkaz:
https://doaj.org/article/9d35a2ef4deb49188851b092086a7efd
Autor:
M. Yamaguchi, Carlos H. Barrios, E. Felip, Z. Andric, M. Mathisen, Eric Dansin, Rafal Dziadziuszko, Shirish M. Gadgeel, Melissa Lynne Johnson, Parneet Cheema, Tony Mok, Jingjing Wang, Silvia Novello, M. Cobo Dols, David R. Gandara, P. Danchaivijitr, S.M. Shagan, Alessandro Morabito, Solange Peters, Erica B. Schleifman
Publikováno v:
Annals of Oncology. 32:S950-S951
Autor:
Erica B Schleifman, Nicole Ali McNeer, Andrew Jackson, Jennifer Yamtich, Michael A Brehm, Leonard D Shultz, Dale L Greiner, Priti Kumar, W Mark Saltzman, Peter M Glazer
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
Biodegradable poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating triplex-forming peptide nucleic acids (PNAs) and donor DNAs for recombination-mediated editing of the CCR5 gene were synthesized for delivery into human peripheral
Externí odkaz:
https://doaj.org/article/9d231e9a17ac4b9681ad99bc3e340c3f
Autor:
Christine Malboeuf, Alan Sandler, Todd Riehl, Doron Lipson, Marcin Kowanetz, David R. Gandara, David Fabrizio, Yan Li, Marcus Ballinger, Priti S. Hegde, Wei Zou, Lukas C. Amler, David S. Shames, Jacob Silterra, Louis Fehrenbacher, Craig Cummings, Achim Rittmeyer, Erica B. Schleifman, Geoff Otto, Sarah M. Paul, Tony Mok, Daniel S. Lieber
Publikováno v:
Nature Medicine. 24:1441-1448
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1 testing is required fo
Autor:
Simonetta Mocci, A. Kinkolykh, Erica B. Schleifman, Nir Peled, Jorge Arturo Alatorre-Alexander, M. Mathisen, Sarah M. Paul, S. Ponce, B. Vicuna, Rafal Dziadziuszko
Publikováno v:
Journal of Thoracic Oncology. 16:S684
Autor:
Teiko Sumiyoshi, Ling Huw, Erica B. Schleifman, Joyce A. O'Shaughnessy, Eloisa Fuentes, Garret Hampton, Rupal Desai, Ling Fu, Jill M. Spoerke, Timothy R. Wilson, Mark R. Lackner, Yuanyuan Xiao, Ilma Abbas, Hartmut Koeppen, Jane Fridlyand, Arjan Gower
Publikováno v:
Breast Cancer Research and Treatment
Breast cancers are categorized into three subtypes based on protein expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/ERBB2). Patients enroll onto experimental clinical trials based o
Autor:
Christine Malboeuf, David S. Shames, Wei Zou, Todd Riehl, David Fabrizio, Alan Sandler, Craig Cummings, Achim Rittmeyer, Lukas C. Amler, G. Otto, Priti S. Hegde, Louis Fehrenbacher, Tony Mok, Erica B. Schleifman, Daniel S. Lieber, Marcin Kowanetz, David R. Gandara, Marcus Ballinger, Sarah M. Paul
Publikováno v:
ResearcherID
Publons
Publons